Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 19];6(6):s72. Available from: https://skin.dermsquared.com/skin/article/view/1829